| Market Cap | 24.79M | P/E | - | EPS this Y | 45.50% | Ern Qtrly Grth | - |
| Income | -20.74M | Forward P/E | -1.42 | EPS next Y | 1.50% | 50D Avg Chg | -7.00% |
| Sales | 1.13M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 4.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -46.00% |
| Recommedations | 2.70 | Quick Ratio | 0.12 | Shares Outstanding | 28.70M | 52W Low Chg | 122.00% |
| Insider Own | 40.04% | ROA | -282.49% | Shares Float | 15.88M | Beta | -0.39 |
| Inst Own | 13.03% | ROE | - | Shares Shorted/Prior | 254.12K/151.06K | Price | 1.49 |
| Gross Margin | 91.56% | Profit Margin | - | Avg. Volume | 91,743 | Target Price | 0.95 |
| Oper. Margin | -4,577.99% | Earnings Date | Nov 7 | Volume | 45,296 | Change | 2.76% |
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
| Maxim Group | Hold | Aug 27, 24 |
| Ascendiant Capital | Buy | Aug 26, 24 |
| HC Wainwright & Co. | Neutral | Aug 23, 24 |
| HC Wainwright & Co. | Buy | Aug 16, 24 |
| HC Wainwright & Co. | Buy | May 31, 24 |
| HC Wainwright & Co. | Buy | May 1, 24 |
| Ascendiant Capital | Buy | Apr 22, 24 |
| Maxim Group | Buy | Sep 27, 23 |
| Maxim Group | Hold | Mar 21, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| TATE JEFFREY | Chief Operating Offi.. Chief Operating Officer | Apr 20 | Buy | 0.71 | 29,941 | 21,258 | 62,101 | 04/24/23 |
| FINE N SCOTT | Chief Executive Offi.. Chief Executive Officer | Apr 20 | Buy | 0.71 | 299,402 | 212,575 | 444,402 | 04/24/23 |
| Sieger Markus | Director Director | Apr 20 | Buy | 0.71 | 59,881 | 42,516 | 161,051 | 04/24/23 |
| Ostronic Francis Patrick | Director Director | Apr 20 | Buy | 0.71 | 59,881 | 42,516 | 222,371 | 04/24/23 |
| Ostronic Francis Patrick | Director Director | Sep 21 | Buy | 1.76 | 5,000 | 8,800 | 150,687 | 09/22/22 |
| Ostronic Francis Patrick | Director Director | May 20 | Buy | 2.02 | 5,000 | 10,100 | 138,525 | 05/23/22 |
| TATE JEFFREY | Chief Operating Offi.. Chief Operating Officer | May 16 | Buy | 2.118 | 3,000 | 6,354 | 32,160 | 05/16/22 |
| TATE JEFFREY | Chief Operating Offi.. Chief Operating Officer | Apr 28 | Buy | 2.64 | 2,000 | 5,280 | 29,160 | 04/29/22 |
| Sieger Markus | Director Director | Mar 29 | Buy | 2.73 | 10,000 | 27,300 | 81,689 | 03/30/22 |
| Ostronic Francis Patrick | Director Director | Jan 24 | Buy | 3.75 | 2,000 | 7,500 | 113,211 | 01/24/22 |
| FINE N SCOTT | Chief Executive Offi.. Chief Executive Officer | Jan 19 | Buy | 3.89 | 5,000 | 19,450 | 134,666 | 01/19/22 |
| Ostronic Francis Patrick | Director Director | Jan 19 | Buy | 4 | 1,132 | 4,528 | 111,211 | 01/19/22 |
| Ostronic Francis Patrick | Director Director | Jan 14 | Buy | 4 | 1,731 | 6,924 | 110,079 | 01/18/22 |